Market Place
Sourcing Support
All News #Library
Biotech
BioCryst Complete Acquisition Astria to Lead HAE Treatment
23 Jan 2026 //
GLOBENEWSWIRE
Astria Stockholders Vote To Approve Acquisition By BioCryst
21 Jan 2026 //
BUSINESSWIRE
Astria Therapeutics Announces Positive Navenibart Data for HAE
06 Nov 2025 //
BUSINESS WIRE
Astria Therapeutics To Present at ACAAI Meeting
31 Oct 2025 //
BUSINESSWIRE
Astria Pharma Launches Navenibart Trial For Hereditary Angioedema
08 Oct 2025 //
PHARMIWEB
Astria Therapeutics Enrolls HAE Patients In EU For Phase 3 Trial
02 Oct 2025 //
BUSINESSWIRE
Astria Therapeutics Reports Phase 1a Trial Success of STAR-0310
17 Sep 2025 //
PHARMAWEB
Kaken Strengthens Late-Stage HAE Portfolio with $32 M Astria Deal
09 Aug 2025 //
FIERCE BIOTECH
Astria Starts Ph 3 Alpha-orbit Trial Of Navenibart In Angioedema
27 Feb 2025 //
BUSINESSWIRE
Astria Starts Ph 1A Trial For Atopic Dermatitis Treatment
23 Jan 2025 //
BUSINESSWIRE
Astria`s STAR-0310 IND Approved For Atopic Dermatitis
10 Dec 2024 //
BUSINESSWIRE
Astria Therapeutics Presents At Allergy And Immunology Meeting
21 Oct 2024 //
BUSINESSWIRE
Astria`s Navenibart Receives FDA Orphan Drug Designation
30 Sep 2024 //
BUSINESSWIRE
Astria Receives Fast Track Designation for STAR-0215 for Treatment of HAE
20 Jul 2023 //
BUSINESSWIRE
Astria to Present STAR-0215 at 13th C1-Inhibitor Deficiency Workshop
28 Apr 2023 //
BUSINESSWIRE
Astria Presents Data Supporting STAR-0215 Profile as Preventative Therapy
24 Feb 2023 //
BUSINESSWIRE
Astria Initiates ALPHA-STAR Phase 1b/2 Trial of STAR-0215 in People with HAE
08 Feb 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.